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esponsibility of Xi’Abstract Liquid chromatography–tandem mass spectrometry (LC–MS/MS) method was used for
simultaneous quantiﬁcation of tolterodine and its metabolite 5-hydroxy methyl tolterodine in rat plasma.
Tolterodine-d6 and 5-hydroxy methyl tolterodine-d14 were used as internal standards (IS). Chromatographic
separation was performed on Ascentis Express RP amide (50 mm 4.6 mm, 2.7 μm) column with an isocratic
mobile phase composed of 10 mM ammonium acetate and acetonitrile in the ratio of 20:80 (v/v), at a ﬂow-rate
of 0.5 mL/min. Tolterodine, tolterodine-d6, 5-hydroxy methyl tolterodine and 5-hydroxy methyl tolterodine-d14
were detected with proton adducts at m/z 326.1-147.1, 332.3-153.1, 342.2-223.1 and 356.2-223.1 in
multiple reaction monitoring (MRM) positive mode respectively. The drug, metabolite and internal standards
were extracted by liquid–liquid extraction method. The method was validated over a linear concentration range
of 20.00–5000.00 pg/mL for tolterodine and 20.00–5000.00 pg/mL for 5-hydroxy methyl tolterodine. This
method demonstrated intra- and inter-day precision of 0.62–6.36% and 1.73–4.84% for tolterodine, 1.38–4.22%
and 1.62–4.25% for 5-hydroxy methyl tolterodine respectively. This method also demonstrated intra- and inter-
day accuracy of 98.75–103.56% and 99.20–104.40% for tolterodine, 98.08–104.67% and 98.73–103.06% forsity. Production and hosting by Elsevier B.V. All rights reserved.
5
f Pharmaceutics, Vignan
, Andhrapradesh 522001, India.
com (R.P. Shaik).
an Jiaotong University.
Fig. 1 Chemical structures of
R.P. Shaik et al.4905-hydroxy methyl tolterodine respectively. Both analytes were found to be stable throughout freeze–thaw
cycles, bench top and postoperative stability studies. This method was successfully applied for the
pharmacokinetic analysis of rat plasma samples following i.v. administration.
& 2013 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Tolterodine tartarate is chemically (R)-N,N-diisopropyl-3-(2-hydroxy-
5-methylphenyl)-3-phenylpropanamine L-hydrogen tartarate. The
molecular formula is C26H37NO7 with a molecular weight of
473.58. Tolterodine is a competitive muscarinic receptor antagonist.
Both urinary bladder contraction and salivation are mediated via
cholinergic muscarinic receptors. After oral administration, tolterodine
is metabolized in the liver, resulting in the formation of the 5-
hydroxymethyl derivative, a major pharmacologically active metabo-
lite. The 5-hydroxymethyl metabolite, which exhibits an antimuscari-
nic activity similar to that of tolterodine, contributes signiﬁcantly to the
therapeutic effect. Both tolterodine and the 5-hydroxymethyl metabo-
lite exhibit a high speciﬁcity for muscarinic receptors, since both show
negligible activity and afﬁnity for other neurotransmitter receptors and
other potential cellular targets, such as calcium channels. Tolterodine
has a pronounced effect on bladder function. The main effects of
tolterodine are an increase in residual urine, reﬂecting an incomplete
emptying of the bladder, and a decrease in detrusor pressure,
consistent with an antimuscarinic action on the lower urinary tract.
Both tolterodine and its active metabolite, 5-hydroxy methyl
tolterodine, act as competitive antagonists at muscarinic receptors.
This results in the inhibition of bladder contraction, a decrease in
detrusor pressure, and an incomplete emptying of the bladder. In a
study with 14C-tolterodine solution in healthy volunteers who
received a 5-mg oral dose, at least 77% of the radiolabeled dose
was absorbed. Cmax and area under the concentration–time curve
(AUC) determined after dosage of tolterodine immediate release
are dose-proportional over the range of 1–4 mg. Cmax and Cmin
levels of tolterodine extended release are about 75% and 150% of
tolterodine immediate release, respectively. Maximum serum
concentrations of tolterodine extended release are observed 2–6 h
after dose administration [1–9].tolterodine, tolterodine-d6, 5-hydroLiterature survey reveals that few analytical methods were
reported for quantiﬁcation of tolterodine by using capillary electro-
phoresis [10], HPLC [11–14], UPLC [15], GC–MS [16], LC–MS
[17–22]. Among all, quantiﬁcation was done in pharmaceutical
compounds [10–14] and biological samples [15–22]. Bioanalysis is
most predominant in clinical pharmacokinetic studies. The bioana-
lytical methods by using LC–MS in human plasma [15–20] and
human urine [15,16,21] were reported. No method was reported for
quantiﬁcation of tolterodine in rat plasma by using LC–MS/MS.
However, only one method was reported where tolterodine was
used as an internal standard [22]. LC–MS/MS has become a
powerful technique in bioanalytical aspect to estimate pharmacoki-
netic parameters [23–25]. The aim of the present study is to develop
and validate a simple, sensitive, rugged, reproducible, and most
economical method for the quantiﬁcation of tolterodine in rat
plasma, which could be applied to the pharmacokinetic study.2. Materials and methods
2.1. Chemicals
Tolterodine, 5-hydroxy methyl tolterodine, tolterodine-d6 and
5-hydroxy methyl tolterodine-d14 (Fig. 1) were obtained from
Aurobindo Pharma Ltd. (Hyderabad, India). Ammonium acetate
(reagent grade) was obtained from sd-ﬁne chemicals (Mumbai,
India). Methanol, acetonitrile and methyl-t-butyl ether (HPLC grade)
were obtained from J.T. Baker (Mumbai, India).
2.2. LC–MS/MS instrument
The 1200 Series HPLC system (Agilent Technologies, Waldbronn,
Germany) was used. Mass spectrometric detection was performedxy methyl tolterodine, and 5-hydroxy methyl tolterodine-d14.
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Toronto, Canada). Data processing was performed on Analyst 1.5.1
software package (SCIEX).2.3. Detection
In the Turbo ion spray positive mode with Unit Resolution,
multiple reaction monitoring (MRM) was used for the detection.
For tolterodine and 5-hydroxy methyl tolterodine the [M−H]+ ions
were monitored at m/z 326.1 and m/z 342.2 as the precursor ion,
and a fragment at m/z 147.1 and m/z 223.1 as the product ion,
respectively. For internal standard tolterodine-d6, 5-hydroxy
methyl tolterodine-d14 the [M−H]+ ions were monitored at m/z
332.3, m/z 356.2 as the precursor ion and a fragment at m/z 153.1
and m/z 223.1 as the product ion, respectively. Mass parameters
were optimized as source temperature 550 1C, nebulizer gas 20
(nitrogen) psi, heater gas 30 (nitrogen) psi, curtain gas 20
(nitrogen) psi, CAD gas 5 (nitrogen) psi, ion spray (IS) voltage
5000 V, source ﬂow rate 500 μL/min without split, entrance
potential 10 V, collision cell exit potential (CXP) 12 V, decluster-
ing potential (DP) 50 V, collision energy 35 V for tolterodine,
tolterodine-d6, 5-hydroxy methyl tolterodine and 5-hydroxy
methyl tolterodine-d14.2.4. Chromatographic conditions
Ascentis Express RP amide (50 mm 4.6 mm, 2.7 μm) was
selected as the analytical column. The mobile phase was composed
of 10 mM ammonium acetate and acetonitrile in the ratio of 20:80
(v/v). The ﬂow rate of the mobile phase was set at 0.5 mL/min.
The column temperature was set at 20 1C. Tolterodine-d6 and
5-hydroxy methyl tolterodine-d14 were found to be appropriate
internal standards in terms of chromatography and extractability.
The retention times of tolterodine, tolterodine-d6, 5-hydroxy
methyl tolterodine, and 5-hydroxy methyl tolterodine-d14 were
found to be approximately 1.970.2 min, 1.970.2 min, 1.270.2 min
and 1.270.2 min, respectively.2.5. Preparation of calibration standards and quality control
(QC) samples
Standard stock solutions of tolterodine, 5-hydroxy methyl tolterodine
(50.00 μg/mL), and tolterodine-d6, 5-hydroxy methyl tolterodine-d14
(50.00 μg/mL) were prepared in methanol. The spiking solutions for
tolterodine-d6 (6000.00 pg/mL) and 5-hydroxy methyl tolterodine-d14
(5000.00 pg/mL) were prepared in 60% methanol from respective
standard stocks. Standard stock solutions and IS spiking solutions
were stored in a refrigerator at 2–8 1C until analysis. Standard stock
solutions were added to drug-free rat plasma to obtain tolterodine/5-
hydroxy methyl tolterodine concentration levels of 20.0, 40.0, 100.0,
250.0, 500.0, 1000.0, 2000.0, 3000.0, 4000.0/4000.0, and 5000.0 pg/
mL for analytical standards and 20.0, 60.0, 1500.0, 3500.0,
3500.00 pg/mL for quality control standards. These standard solutions
were stored at −30 1C in a freezer until analysis. The aqueous
standards were prepared in reconstitution solution (10 mM ammonium
acetate and acetonitrile in the ratio of 20:80 (v/v)), for validation
exercises until analysis.2.6. Sample preparation
Liquid–liquid extraction was used to isolate tolterodine/5-hydroxy
methyl tolterodine and its respective IS from rat plasma. 50 μL
of IS (6000.00/5000.00 pg/mL) and 100 μL of plasma sample
(respective concentration) were added into labeled polypropylene
tubes or ria vials, placed in an icebath and vortexed brieﬂy. Then
2.5 mL of extraction solvent (methyl t-butyl ether) was added,
closed with tight caps and vortexed for 10 min followed by
centrifugation at 4000 rpm for 10 min at 20 1C. Then the super-
natant from each sample was transferred into labeled polypropy-
lene tubes. After that, the samples were evaporated to dryness at
40 1C under nitrogen. The dried residue samples were reconsti-
tuted with 100 μL of reconstitution solution (acetonitrile:10 mM
ammonium acetate:80:20, v/v) and vortexed brieﬂy. Finally,
sample from each tube was transferred into autosampler vials for
injection.
2.7. Method validation
2.7.1. Linearity, precision and accuracy
The analytical curves were constructed using concentrations
ranging from 20.00 to 5000.00 pg/mL for tolterodine and 20.00
to 5000.00 pg/mL for 5-hydroxy methyl tolterodine in rat plasma.
Calibration curves were obtained by weighted 1 linear regres-
sion analysis. The peak area ratio of tolterodine to tolterodine-d6
was plotted against the tolterodine concentration in pg/mL.
Similarly, the peak area ratio of 5-hydroxy methyl tolterodine
to 5-hydroxy methyl tolterodine-d14 was plotted against the
5-hydroxy methyl tolterodine concentration in pg/mL. The corre-
lation coefﬁcients40.9998, 0.9987 were obtained for both tolter-
odine and 5-hydroxy methyl tolterodine respectively. Precision
and accuracy for the back calculated concentrations of the
calibration points should be within ≤15% and 715% of their
nominal values [26]. However, for LLOQ the precision and accuracy
should be within ≤20% and 720% of their nominal values.
2.7.2. Recovery
The extraction recovery of tolterodine/5-hydroxy methyl tolter-
odine and tolterodine-d6/5-hydroxy methyl tolterodine-d14 from
rat plasma was determined by analyzing quality control samples.
Recovery at three concentrations (60.00, 1500.00 and 3500.00 pg/mL)
was determined by comparing peak areas obtained from the plasma
sample and those from the standard solution spiked with the blank
plasma residue. A recovery of more than 50% was considered adequate
to obtain the required sensitivity.
2.7.3. Limits of quantiﬁcation (LOQ) and detction (LOD)
The response (peak area) was determined in blank plasma samples
(six replicates from different plasma samples) and spiked LOQ
sample prepared from the same plasma. The peak area of blank
samples should not be more than 20% of the mean peak area of
LOQ of tolterodine/5-hydroxy methyl tolterodine and not more
than 5% of tolterodine-d6/5-hydroxy methyl tolterodine-d14. The
precision and mean accuracy of the back calculated LOQ replicate
concentrations must be ≤20 and 720%, respectively.
LOD is a parameter that provides the lowest concentration in a
sample that can be detected from background noise but not
quantitated. LOD was determined using the signal-to-noise ratio
(S/N) of 3:1 by comparing test results from samples with known
concentrations of analyte with blank samples.
Fig. 2 Mass spectra of (A) tolterodine parent ion, (B) tolterodine product ion, (c) tolterodine-d6 parent ion and (D) tolterodine-d6 product ion.
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Fig. 3 Mass spectra of (A) 5-hydroxy methyl tolterodine parent ion, (B) 5-hydroxy methyl tolterodine product ion, (C) 5-hydroxy methyl
tolterodine-d14 parent ion and (D) 5-hydroxy methyl tolterodine-d14 product ion.
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Low quality control (LQC) and high quality control (HQC)
samples (n¼6) were retrieved from the deep freezer after three
freeze–thaw cycles according to the clinical protocols. Samples
were stored at −30 1C in three cycles of 24, 36 and 48 h. In
addition, the long-term stability of tolterodine/5-hydroxy methyl
tolterodine in quality control samples was also evaluated by
analysis after 65 days of storage at −30 1C. Autosampler stability
was studied following 34 h storage period in the autosampler tray
with control concentrations. Bench top stability was studied for a
26 h period with control concentrations. Stability samples were
processed and extracted along with the freshly spiked calibration
curve standards. The precision and accuracy for the stability samples
must be within ≤15 and 715% of their nominal concentrations,
respectively.
2.8. Application to pharmacokinetic study in rat plasma
The validated method has been successfully used to quantify
tolterodine, 5-hydroxy methyl tolterodine concentrations in rat
plasma. The study was conducted according to current GCP
guidelines [26–28]. Before conducting the study it was also
approved by an authorized animal ethics committee. Male
Sprague–Dawley rats were obtained from Vignan College of
Pharmacy, Vadlamudi, Guntur, A.P, India. After i.v. administra-
tion of 0.072 mg of tolterodine/200 g body weight of rat via left
femoral vein 0.4 mL of blood samples for analytical determina-
tions were collected via the right femoral vein at speciﬁc timeFig. 4 Chromatogram of blank rat plasma: (A) tolterodine, (B) tolterod
tolterodine-d14.intervals (0.15, 0.25, 0.66, 1, 3, 5, 9, 17, 23 h). The blood samples
were collected in separate tubes containing K2EDTA as an
anticoagulant. The plasma from these samples was separated by
centrifugation at 3000 rpm within the temperature range of 2–8 1C. The
plasma samples thus obtained were stored at −30 1C until analysis.
After analysis the pharmacokinetic parameters were computed using
WinNonlins software version 5.2.
3. Results and discussion
3.1. Method development
LC–MS/MS has been used as one of the most powerful analytical
techniques in clinical pharmacokinetics for its selectivity, sensitivity
and reproducibility. The goal of this work was to develop and validate
a simple, sensitive and rapid assay method for the quantitative
determination of tolterodine, 5-hydroxy methyl tolterodine from plasma
samples. A simple liquid–liquid extraction technique was utilized in the
extraction of tolterodine, 5-hydroxy methyl tolterodine and tolterodine-
d6, 5-hydroxy methyl tolterodine-d14 from the plasma samples.
Chromatographic conditions, especially the composition and nature
of the mobile phase, were optimized through several trials to achieve
best resolution and increase the signal of tolterodine, 5-hydroxy methyl
tolterodine and tolterodine-d6, 5-hydroxy methyl tolterodine-d14.
The MS optimization was performed by direct infusion of solutions
of both tolterodine, 5-hydroxy methyl tolterodine and tolterodine-d6,
5-hydroxy methyl tolterodine-d14 into the ESI source of the mass
spectrometer.ine-d6, (C) 5-hydroxy methyl tolterodine, and (D) 5-hydroxy methyl
Fig. 5 Chromatogram of tolterodine, tolterodine-d6 and 5-hydroxy methyl tolterodine, 5-hydroxy methyl tolterodine-d14 at LOQ level.
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were optimized to obtain a better spray shape, resulting in better
ionization. Tolterodine, tolterodine-d6, 5-hydroxy methyl tolter-
odine and 5-hydroxy methyl tolterodine-d14 were detected with
proton adducts at m/z 326.1-147.1, 332.3-153.1, 342.2-223.1
and 356.2-223.1 in multiple reaction monitoring (MRM) posi-
tive mode respectively (Figs. 2A–D, 3A–D). After the MRM
channels were tuned, the mobile phase was changed from an
aqueous phase to more organic phase to obtain a fast and selective
LC method. A good separation and elution were achieved using
10 mM ammonium acetate:acetonitrile (20:80, v/v) as the mobile
phase, at a ﬂow-rate of 0.5 mL/min and injection volume of 10 μL.
3.2. Method validation[26]
3.2.1. Speciﬁcity
The analysis of tolterodine, 5-hydroxy methyl tolterodine and
tolterodine-d6, 5-hydroxy methyl tolterodine-d14 using MRM
function was highly selective with no interfering compounds.Table 1 Calibration curves for tolterodine and 5-hydroxy methyl to
Analyte Spiking plasma
concentration (pg/mL)
Con
(me
Tolterodine 20.00 2
40.00 4
100.00 9
250.00 24
500.00 50
1000.00 101
2000.00 202
3000.00 302
4000.00 396
5000.00 498
5-Hydroxy methyl tolterodine 20.00 2
40.00 3
100.00 10
250.00 24
500.00 50
1000.00 101
2000.00 201
3000.00 300
4000.00 400
5000.00 502
Table 2 Precision and accuracy (analysis with spiking plasma samp
methyl tolterodine.
Analyte Spiking plasma
concentration (pg/mL)
Inter-day
Concentration measured
(mean7SD) (n¼6; pg/mL)
Tolterodine 20.00 19.9071.26
60.00 59.2572.18
1500.00 1553.33718.62
3500.00 3616.67722.51
5-Hydroxy
methyl
tolterodine
20.00 19.7370.83
60.00 58.8571.42
1500.00 1520.00720.98
3500.00 3663.33780.42Fig. 4 shows the chromatograms of one blank rat plasma.
Chromatograms obtained from plasma spiked with tolterodine
(20.00 pg/mL), 5-hydroxy methyl tolterodine (20.00 pg/mL),
tolterodine-d6 (6000.00 pg/mL) and 5-hydroxy methyl tolterodine-
d14 (5000.00 pg/mL) are shown in Fig. 5.
3.2.2. Linearity, precision and accuracy
Calibration curves were plotted as the peak area ratio (tolterodine/
tolterodine-d6) versus (tolterodine) concentration for tolterodine
and the peak area ratio (5-hydroxy methyl tolterodine/5-hydroxy
methyl tolterodine-d14) versus (5-hydroxy methyl tolterodine)
concentration for 5-hydroxy methyl tolterodine. Calibration
was found to be linear over the concentration range of 20.00–
5000.00 pg/mL for tolterodine and 20.00–5000.00 pg/mL for
5-hydroxy methyl tolterodine. The precision (CV%) for tolterodine,
5-hydroxy methyl tolterodine was less than 2.26% and 3.66%
respectively. The accuracy ranged from 97.36% to 101.68%
for tolterodine and 97.12% to 101.62% for 5-hydroxy methyl
tolterodine. The determination coefﬁcients (r2) for tolterodine andlterodine.
centration measured
an7SD; pg/mL)
CV (%) (n¼5) Accuracy (%)
0.0870.19 0.96 100.40
0.1470.62 1.55 100.35
8.3471.78 1.81 98.34
3.4073.21 1.32 97.36
8.4074.83 0.95 101.68
0.20716.89 1.67 101.02
8.00731.14 1.54 101.40
6.00768.41 2.26 100.87
4.00759.41 1.50 99.10
0.00786.60 1.74 99.60
0.1870.36 1.77 100.90
9.2871.44 3.66 98.20
0.2271.29 1.29 100.22
2.8073.35 1.38 97.12
1.2078.58 1.71 100.24
6.20726.78 2.64 101.62
6.00735.07 1.74 100.80
4.00726.08 0.87 100.13
8.00772.94 1.82 100.20
4.007136.12 2.71 100.48
les at four different concentrations) for tolterodine and 5-hydroxy
Inter-day
CV
(%)
Accuracy
(%)
Concentration measured
(mean7SD) (n¼6; pg/mL)
CV
(%)
Accuracy
(%)
6.36 99.50 19.8470.96 4.84 99.20
3.69 98.75 60.0971.85 3.08 100.14
1.20 103.56 1566.00729.43 1.88 104.40
0.62 103.33 3627.00762.87 1.73 103.63
4.22 98.67 20.0770.85 4.25 100.35
2.41 98.08 59.2471.76 2.97 98.73
1.38 101.33 1511.33724.46 1.62 100.76
2.20 104.67 3607.00773.40 2.03 103.06
Table 3 Stability of the samples for tolterodine and 5-hydroxy methyl tolterodine.
Stability Plasma concentration
(pg/mL)
Tolterodine 5-Hydroxy methyl tolterodine
Concentration measured
(mean7SD) (n¼6; pg/mL)
CV (%)
(n¼6)
Concentration measured
(mean7SD) (n¼6; pg/mL)
CV (%)
(n¼6)
Room temperature stability (26 h) 60.00 60.6771.29 2.13 58.8870.45 0.77
3500.00 3571.67743.55 1.22 3565.00747.64 1.34
Autosampler stability (34 h) 60.00 62.2571.01 1.62 58.4871.79 3.05
3500.00 3583.33743.20 1.21 3666.677105.96 2.89
Freeze–thaw stability (3 cycles) 60.00 58.9570.88 1.50 58.5571.00 1.70
3500.00 3576.67752.79 1.48 3548.33763.06 1.78
Long term stability (65 days) 60.00 60.3771.18 1.95 59.0370.83 1.41
3500.00 3601.67731.25 0.87 3543.33742.27 1.19
Table 4 Pharmacokinetic data for tolterodine and 5-hydroxy
methyl tolterodine in rat plasma.
Pharmacokinetic
parameter
Tolterodine 5-Hydroxy methyl
tolterodine
Cmax (pg/mL) 4482.08 3854.59
Tmax (h) 0.25 0.25
AUC0−t (pg h/mL) 14,582.32 12,540.83
AUC0−inf (pg h/mL) 14,681.03 12,625.72
T1/2 (h) 3.25 3.25
Kel 0.21324 0.21324
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respectively for all curves (Table 1). Precision and accuracy for this
method was controlled by calculating the intra- and inter-batch
variations of QC samples in six replicates at four concentrations
(20.00, 60.00, 1500.00 and 3500.00 pg/mL) for tolterodine and
5-hydroxy methyl tolterodine as shown in Table 2. This method
demonstrated intra- and inter-day precision of 0.62–6.36% and
1.73–4.84% for tolterodine, 1.38–4.22% and 1.62–4.25% for 5-
hydroxy methyl tolterodine. This method demonstrated intra- and
inter-day accuracy 98.75–103.56% and 99.20–104.40% for tolter-
odine, 98.08–104.67% and 98.73–103.06% for 5-hydroxy methyl
tolterodine. These results indicate the adequate reliability and
reproducibility of this method within the analytical range.
3.2.3. Stability
Quantiﬁcation of tolterodine and 5-hydroxy methyl tolterodine in
plasma subjected to 3 freeze–thaw (from −30 1C to room
temperature) cycles showed the stability of the analyte and its
metabolite. The concentrations ranged from 97.98% to 100.05%
for tolterodine and 99.35% to 99.44% for 5-hydroxy methyl
tolterodine of the theoretical values. No signiﬁcant degradation
of tolterodine and 5-hydroxy methyl tolterodine was observed
even after 34 h storage period in the autosampler tray and the ﬁnal
concentrations of tolterodine and 5-hydroxy methyl tolterodine
were between 100.23% and 103.46% and 95.24% and 102.76% of
the theoretical values. The room temperature stability of tolter-
odine and 5-hydroxy methyl tolterodine in QC samples after 26 h
was also evaluated. The concentrations ranged from 99.91% to
100.83% for tolterodine and 99.91% to 99.92% for 5-hydroxy
methyl tolterodine of the theoretical values. In addition, the long-
term stability of tolterodine and 5-hydroxy methyl tolterodine in
QC samples after 65 days of storage at −30 1C was also evaluated.
The concentrations ranged from 100.33% to 100.75% for tolter-
odine and 99.30% to 100.17% for 5-hydroxy methyl tolterodine of
the theoretical values. These results conﬁrmed the stability of
tolterodine and 5-hydroxy methyl tolterodine in rat plasma for at
least 65 days at −30 1C (Table 3).
3.2.4. Recovery
The recovery following the sample preparation using the liquid–
liquid extraction method with t-butyl methyl ether was calculated
by comparing the peak areas of drug in plasma samples with the
peak area ratios of solvent samples and was estimated at control
levels of drug. The recovery values of tolterodine (at concentrations
60.0, 1500.0 and 3500.0 pg/mL) and 5-hydroxy methyl tolterodine
(at concentrations 60.0, 1500.0 and 3500.0 pg/mL) were found to be98.32%, 91.38%, 88.35%, and 96.82%, 81.55%, 82.92%, respectively.
The overall mean recovery values of tolterodine, 5-hydroxy methyl
tolterodine, tolterodine-d6 and 5-hydroxy methyl tolterodine-d14 were
92.68%, 87.09%, 85.45% and 90.98% respectively.
3.2.5. LOQ and LOD
The limit of quantiﬁcation LOQ for this method was proven as the
lowest concentration of the calibration curve which was proven as
20.00 pg/mL for tolterodine and 5-hydroxy methyl tolterodine.
The LOD was determined using aqueous solutions. For
tolterodine 10 μL of a 2.0 pg/mL solution was injected to give
an on-column mass of 20.0 fg and for 5-hydroxy methyl tolter-
odine, 10 μL of a 0.5 pg/mL solution was injected to give an
on-column mass of 5.0 fg.
3.3. Pharmacokinetics and statistical analysis
The validated method has been successfully applied to quantify
tolterodine and 5-hydroxy methyl tolterodine concentrations after
i.v. administration of a single-dose (0.072 mg/200 g) tolterodine in
rats. The pharmacokinetic parameters evaluated were Cmax (max-
imum observed drug concentration during the study), AUC0–23 (area
under the plasma concentration–time curve measured for 23 h, using
the trapezoidal rule), Tmax (time to observe maximum drug
concentration), Kel (apparent ﬁrst order terminal rate constant
calculated from a semi-log plot of the plasma concentration versus
time curve, using the method of least square regression) and T1/2
(terminal half-life as determined by quotient 0.693/Kel) [27,28].
Pharmacokinetic details are shown in Table 4. The mean concentra-
tion versus time proﬁle of tolterodine and 5-hydroxy methyl
tolterodine in rat plasma is shown in Fig. 6.
Fig. 6 Mean plasma concentrations versus time graph of tolterodine and 5-hydroxy methyl tolterodine after intravenous administration of
0.072 mg/200 g tolterodine in male rats.
R.P. Shaik et al.4984. Conclusions
In this article, we have reported the use of LC–MS/MS for the
accurate, precise and reliable measurement of tolterodine and 5-
hydroxy methyl tolterodine in rat plasma after i.v. administration
of 0.072 mg/200 g tolterodine to healthy rats. The method
described here is fast, robust, and sensitive. Each sample requires
less than 3.5 min of analysis time.
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